Tofacitinib for refractory ocular mucous membrane pemphigoid

American Journal of Ophthalmology Case Reports

Philip L. Custer¹  Todd P. Margolis²  Hayley James²  Grace L. Paley²  Michael A. Paley²  Richard Brasington² 

[1]Division of Rheumatology, Department of Medicine, Washington University in Saint Louis, Center for Advanced Medicine, 5th floor Suite C, 4921 Parkview Place, Saint Louis, MO, 63110, USA

[2]Department of Ophthalmology and Visual Sciences, Washington University in Saint Louis, Center for Outpatient Health, 6th floor, 4901 Forest Park Avenue, Saint Louis, MO, 63110, USA

关键词: Ocular cicatricial pemphigoid;    Mucous membrane pemphigoid;    Tofacitinib;    JAK;    STAT;    JAK inhibitor;   

DOI  :  

来源: DOAJ

【 摘 要 】

Purpose: To report the successful use of tofacitinib in the treatment of refractory ocular mucous membrane pemphigoid (MMP). Observations: Two patients with ocular MMP presented with refractory disease after failure of multiple therapies. Treatment with tofacitinib led to durable control of conjunctival inflammation within 8 weeks and no apparent progression of sub-conjunctival fibrosis. One patient maintained absence of apparent disease activity over 16 months of follow-up. Cessation of tofacitinib in the other patient led to disease relapse which was reversed by re-initiation of therapy. Conclusions and importance: Small molecule inhibitors of Janus kinases, such as tofacitinib, may offer an effective treatment option for refractory ocular MMP.

【 授权许可】

Unknown